25422-31-5 Usage
Description
Fibrinopeptide A (FPA), Human, is a peptide derived from the N-terminal Aα region of the fibrinogen protein upon cleavage by thrombin. It is composed of 16 amino acids and plays a crucial role in various biological processes and applications.
Uses
Used in Research and Diagnostics:
Fibrinopeptide A, Human is used as a reagent for protein control experiments in sandwich ELISA microarray assays. This application is essential for distinguishing between plasma and serum fibrinogen samples, which aids in understanding the differences in their properties and functions.
Used in Mass Spectrometry:
Fibrinopeptide A, Human is used as a component in peptide mixtures, such as those containing bovine serum albumin (BSA), to study the relationship between fragmentation voltage and peptide ion drift time in ion mobility spectrometry coupled with mass spectrometry (IMS-MS). This application helps researchers optimize the conditions for peptide analysis and improve the accuracy of mass spectrometry techniques.
Biochem/physiol Actions
Fibrinogen plays essential roles in coagulation of blood, wound healing, platelet aggregation and has roles in various other physiological processes. Increase in the levels of fibrinopeptide A (FPA) is found in multiple disorders such as coronary artery disease, disseminated intravascular coagulation, arterial thrombosis, deep venous thrombosis and cancers.
Check Digit Verification of cas no
The CAS Registry Mumber 25422-31-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,5,4,2 and 2 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 25422-31:
(7*2)+(6*5)+(5*4)+(4*2)+(3*2)+(2*3)+(1*1)=85
85 % 10 = 5
So 25422-31-5 is a valid CAS Registry Number.
InChI:InChI=1/C63H97N19O26/c1-29(2)19-37(57(102)73-32(6)53(98)76-35(15-17-48(91)92)55(100)70-24-43(85)68-23-42(84)69-25-46(88)82-51(30(3)4)61(106)77-36(62(107)108)13-10-18-67-63(65)66)79-58(103)38(20-33-11-8-7-9-12-33)80-59(104)39(21-49(93)94)75-45(87)27-71-54(99)34(14-16-47(89)90)74-44(86)26-72-56(101)41(28-83)81-60(105)40(22-50(95)96)78-52(97)31(5)64/h7-9,11-12,29-32,34-41,51,83H,10,13-28,64H2,1-6H3,(H,68,85)(H,69,84)(H,70,100)(H,71,99)(H,72,101)(H,73,102)(H,74,86)(H,75,87)(H,76,98)(H,77,106)(H,78,97)(H,79,103)(H,80,104)(H,81,105)(H,82,88)(H,89,90)(H,91,92)(H,93,94)(H,95,96)(H,107,108)(H4,65,66,67)/t31-,32-,34-,35-,36-,37?,38-,39-,40-,41-,51-/m0/s1
25422-31-5Relevant articles and documents
Fibrinogen-coated microspheres
-
, (2008/06/13)
The invention provides compositions comprising microspheres of fibrinogen-coated cross-linked albumin microspheres having a size range of primarily from about 100 to about 5000 nanometers diameter, wherein the composition is substantially free microspheres and microsphere aggregates having a diameter of more than 10 micrometers. At least a portion of the fibrinogen on the surface of the microspheres is covalently attached. The particles of the invention are useful for reducing bleeding time when administered to a human or other animal.
